Showing results (1-10 of 870) with videos related to

Sort By:
Pageof 87
Cost Effectiveness and Resource Allocation : C/E|December 12, 2022
Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspectiveLineo Marie Matsela, Susan Cleary, Thomas Wilkinson
Cost Effectiveness and Resource Allocation : C/E|December 12, 2022
Health economic analysis of third-line interventions in diffuse large B-cell lymphomas in Germany: applying the efficiency frontierFlorian Jakobs, Julia Jeck, Paymon Ahmadi, et al.
Cost Effectiveness and Resource Allocation : C/E|October 12, 2020
Correction to: HTA and MCDA solely or combined? The case of priority-setting in ColombiaHéctor E Castro, Ornella Moreno-Mattar, Juan C Rivillas
Cost Effectiveness and Resource Allocation : C/E|June 16, 2021
Cost-effectiveness analysis of oral nutritional supplements with nutritional counselling in head and neck cancer patients undergoing radiotherapyBeatrice Martin, Emanuele Cereda, Riccardo Caccialanza, et al.
Cost Effectiveness and Resource Allocation : C/E|July 8, 2021
Health technology assessment in sub-Saharan Africa: a descriptive analysis and narrative synthesisSamantha Hollingworth, Ama Pokuaa Fenny, Su-Yeon Yu, et al.
Cost Effectiveness and Resource Allocation : C/E|October 28, 2020
An exploratory study to estimate cost-effectiveness threshold value for life saving treatments in western IranNajmeh Moradi, Abraha Woldemichael, Parisa Malekian, et al.
Cost Effectiveness and Resource Allocation : C/E|January 12, 2023
Clinical and economic benefits of image-guided system in functional endoscopicsinus surgery: a retrospective chart review study in ChinaZaixing Wang, Chunling Liu, Baoying Tan, et al.
Cost Effectiveness and Resource Allocation : C/E|January 16, 2023
Direct and indirect medical costs of bladder cancer in IranMehdi Raadabadi, Rajabali Daroudi, Kazem Zendehdel, et al.
Cost Effectiveness and Resource Allocation : C/E|January 16, 2023
Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in SpainDolores Isla, Marta Lopez-Brea, María Espinosa, et al.
Cost Effectiveness and Resource Allocation : C/E|January 16, 2023
Systematic review of economic evaluations on stereotactic ablative radiotherapy (SABR) compared to other radiotherapy techniques or surgical procedures for early-stage non-small cell lung cancerFernando Henrique de Albuquerque Maia, Luciana Martins Rozman, Heloisa de Andrade Carvalho, et al.
Pageof 87